2seventy bio, Inc.
TSVT
$4.98
$0.010.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 37.86M | 45.62M | 44.12M | 71.20M | 100.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.86M | 45.62M | 44.12M | 71.20M | 100.39M |
| Cost of Revenue | 99.48M | 136.35M | 178.53M | 223.57M | 247.68M |
| Gross Profit | -61.62M | -90.73M | -134.41M | -152.36M | -147.29M |
| SG&A Expenses | 43.92M | 51.60M | 51.72M | 61.35M | 69.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.40M | 187.95M | 230.26M | 284.92M | 317.09M |
| Operating Income | -105.54M | -142.33M | -186.14M | -213.72M | -216.70M |
| Income Before Tax | -57.25M | -94.55M | -156.25M | -223.22M | -217.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.25 | -94.55 | -156.25 | -223.22 | -217.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.25M | -94.55M | -156.25M | -223.22M | -217.57M |
| EBIT | -105.54M | -142.33M | -186.14M | -213.72M | -216.70M |
| EBITDA | -98.45M | -133.86M | -176.56M | -203.58M | -206.42M |
| EPS Basic | -1.10 | -1.83 | -3.04 | -4.34 | -4.41 |
| Normalized Basic EPS | -1.08 | -1.54 | -2.05 | -2.37 | -2.50 |
| EPS Diluted | -1.12 | -1.86 | -3.07 | -4.35 | -4.42 |
| Normalized Diluted EPS | -1.07 | -1.53 | -2.04 | -2.37 | -2.50 |
| Average Basic Shares Outstanding | 208.85M | 207.90M | 206.82M | 205.60M | 197.00M |
| Average Diluted Shares Outstanding | 211.68M | 210.73M | 209.64M | 205.60M | 197.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |